H2A.Z (H2A.Z.1) |
Colorectal cancer |
Overexpression |
N.D. |
[82] |
|
Undifferentiated cancers |
Overexpression |
N.D. |
[83] |
|
Metastatic breast carcinoma |
Overexpression |
N.D. |
[84] |
|
Primary breast cancer |
Overexpression |
ER alpha- and Myc-dependent upregulation |
[8] |
|
Breast cancer (MCF7 cell line) |
Overexpression |
Increased proliferation |
[14] |
|
Breast cancer |
Overexpression |
H2A.Z recruited at promoters of ERalpha target genes |
[17] |
|
Melanoma |
Overexpression |
N.D. |
[12] |
|
Prostate cancer (LNCaP cell line) |
Overexpression |
Myc-mediated H2AFZ upregulation |
[91] |
|
Prostate cancer (LNCap xenograft) |
N.D. |
H2A.Zub evicted from PSA promoter/enhancer upon activation |
[90] |
|
Prostate cancer (LNCaP cell line) |
N.D. |
H2A.Zac associated with oncogene activation,unmodified H2A.Z with tumor-suppressor silencing |
[48] |
H2A.X |
B-CLL and T-PLL |
Translocations and deletions chr 11q23 |
Increased genome instability |
[130–132] |
|
Head and neck squamous cell carcinoma |
Gene deletion |
Increased genome instability |
[133] |
|
Non-Hodgkin lymphoma |
Gene mutation |
Increased genome instability |
[135] |
|
Gastrointestinal stromal tumor |
Upregulation |
Promote apoptosis upon the treatment with a kinase inhibitor |
[138] |
|
Breast cancer |
Gene deletion |
Increased genome instability |
[134] |
mH2A.1 |
Lung cancer |
Reduced protein levels/splicing defects |
Suppression of cell proliferation via reduced PARP-1 |
[10, 13] |
|
Breast cancer |
Reduced protein levels/splicing defects |
N.D. |
[10, 13] |
|
Melanoma |
Transcriptional downregulation |
Upregulation of CDK8 |
[12] |
|
Testicular, bladder, ovarian, cervical, endometrial cancers |
Splicing defects |
N.D. |
[13] |
|
Colon cancer |
Reduced protein levels and splicing defects |
N.D. |
[9, 13] |
mH2A.2 |
Lung |
Reduced protein levels |
N.D. |
[10] |
|
Breast |
Reduced protein levels |
N.D. |
[10] |
|
Melanoma |
Transcriptional downregulation |
Upregulation of CDK8 |
[12] |
CENP-A |
Colorectal cancer |
Overexpression |
Aneuploidy |
[222] |
|
Invasive testicular germ cell tumors |
Overexpression |
N.D. |
[224] |
|
HCC |
Overexpression |
Deregulation of cell cycle and apoptotic genes |
[226] |
|
Breast cancer |
Overexpression |
N.D. |
[225] |
|
Lung adenocarcinoma |
Overexpression |
N.D. |
[223] |
H3.3 |
Carcinoma of the esophagus |
Overexpression |
N.D. |
[262] |
|
GBM |
Mutation (K27M, G34V/R) |
N.D. |
[15] |
|
Pediatric DIPG |
Mutation (K27M, G34V/R) |
Inhibition of EZH2 activity, reduced H3K27me3 |
[16, 263] |